Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMP 201 in recurrent low-grade serous ovarian cancer
2024-516986-35-00Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of avutometinib and defactinib in low-grade serous ovarian carcinoma (LGSOC) and low-grade serous peritoneal adenocarcinoma (4 arms), sponsored by Verastem Oncology. Primary endpoint: Confirmed overall response rate. Started Sep 2021; status: completed.
02
Drugs
avutometinibdefactinib
03
Conditions
low-grade serous ovarian carcinoma (LGSOC)low-grade serous peritoneal adenocarcinoma
Beyond the preview
Go deeper on 2024-516986-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516986-35-00.